On July 23, JOINN rose 5.35% in regular trading, trading at HK$26.14/share, with turnover of HK$61.61 million, as the stock continued its upward momentum driven by institutional accumulation and sector tailwinds.

On the news front, Barclays PLC disclosed on July 20 that it had acquired approximately 3.28 million shares of JOINN on July 15 at an average price of HK$24.25, bringing its total holding to approximately 7.29 million shares or 6.12% of the company. The total transaction value was approximately HK$79.54 million. Meanwhile, the broader CXO sector continues to strengthen, with peers WUXI BIO up 2.01% and INSILICO up 5.33% today.

The rally also builds on the company's H1 earnings forecast released on July 14, projecting net profit of RMB 600 million to 900 million, representing year-over-year growth of 884.9% to 1,377.4%. The surge was primarily driven by biological asset fair value gains of approximately RMB 703 million to 777 million, as experimental monkey market prices surpassed RMB 200,000 per unit. Core laboratory services revenue is expected to grow only 0% to 10.5% year-over-year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)